Join our daily newsletter At The Bell to receive exclusive market insights
- Immutep (IMM) has enrolled and safely dosed patients for the second stage of its study on head and neck cancer
- The company develops LAG-3-related immunotherapeutic products for treating cancer and autoimmune disease
- The TACTI-002 phase two study evaluates second line head and neck squamous cell carcinoma (HNSCC) being treated with Immutep’s lead product candidate, eftilagimod alpha, in combination with MSD’s KEYTRUDA treatment
- Immutep’s shares are up 1.23 per cent, trading at 41.0 cents
Sydney-based biotechnology company Immutep (IMM) has enrolled and safely dosed patients for the second stage of its study on head and neck cancer.
The company develops LAG-3-related immunotherapeutic products for treating cancer and autoimmune disease.
Specifically, Immutep’s TACTI-002 phase two study evaluates second line head and neck squamous cell carcinoma (HNSCC) being treated with Immutep’s lead product candidate, eftilagimod alpha, in combination with MSD’s KEYTRUDA treatment.
Immutep reported encouraging interim data from the study at the Society for Immunotherapy of Cancer 35th Anniversary 2020 Annual Meeting.
The recruitment of an additional 74 patients with first-line non-small-cell lung carcinoma (NSCLC) in accordance with the TACTI-002 collaboration trial expansion plans has commenced. Now, four more patients have been recruited, adding to the 36 patients already enrolled prior to the expansion.
In total, 40 of 110 patients with first-line NSCLC have now been recruited in part A of the TACTI-002 study.
The company expects to report more data from the trial in the first half of 2021.
Immutep’s shares are up 1.23 per cent, trading at 41 cents at 11:45 am AEDT.
